At Mabloc, we’ve developed the BRAID™ platform—Broadly Reactive Antibody Isolation & Development—to advance therapeutic development. Combining AI, next-gen sequencing, and high-throughput lab technologies, BRAID™ isolates rare, broadly reactive antibodies capable that can target multiple diseases and genetic variations. This approach accelerates the journey from discovery to clinical readiness, delivering life-changing therapies at speed and scale.
Supported by a team of experts in antibody design, optimization, and validation, BRAID™ processes billions of antibody sequences, pinpointing the rare candidates with the highest potential. Our approach ensures that therapies reach patients faster, transforming the way we approach modern medicine.
BRAID™ identifies antibodies that can address a wide range of diseases and genetic variations. This adaptability allows a single treatment to target multiple conditions, improving cost-efficiency and scalability.
Using AI to harvest and analyze thousands of antibody sequences, BRAID™ pinpoints the most promising candidates, shortening development timelines and improving outcomes.
Our antibodies are engineered for maximum therapeutic effect with minimal dosages, ensuring treatments are effective and support patient outcomes.
Validated in non-human primates, our antibodies mimic human immune responses, ensuring safety and efficacy before entering clinical trials. This rigorous validation process ensures research accuracy and reliability.
.jpg)
We develop proprietary immunization regimens tailored to elicit a precise immune response in non-human primates, targeting specific pathogens.
The immunogen is administered to non-human primates, initiating an immune response that generates a broad range of antibodies.
Hundreds of thousands of antibody sequences generated by the immune response are collected and analyzed to provide a wide range of potential therapeutic candidates.
Using proprietary bioinformatics tools powered by AI and machine learning, we analyze the antibody sequences to identify those with the highest therapeutic potential.
Selected antibodies are refined through affinity maturation and protein engineering to improve their binding ability and adapt their functional properties for therapeutic use.
"At Mabloc, we’re focused on one thing: making sure our therapies reach people as soon as possible. With BRAID™, we’re not waiting around for years—we’re pushing to get life-saving treatments into the hands of those who need them, now. I always tell my team, ‘We’re doing this today, not in some distant future.’ That’s what drives us every day.”
